FDA Clearance Tracker · K242706
Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio
Last checked: Nov 19, 2026Latest source record: May 16, 2025 (this decision)Source: openFDAMethods & limitations
Decided
May 16, 2025
Substantially Equivalent
Time to decision
249 days
Received Sep 9, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K242706
- Device name
- Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio
- Applicant
- Fujirebio Diagnostics,Inc.
- Applicant location
- Malvern, PA
- Received
- Sep 9, 2024
- Decided
- May 16, 2025
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.5840
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code SET (Immunoassay Blood Test For Amyloid Pathology Assessment).
- It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).
Source documents
- FDA database record for K242706
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Fujirebio Diagnostics,Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K250925 · Decided Dec 16, 2025 · 264 days after receipt
Device type: Cytokeratin Fragments 21-1 Eia Kit (OVK) · Laboratory Medicine & Pathology
- Lumipulse G ß-Amyloid Ratio (1-42/1-40)New device typeBreakthroughDe Novo
DEN200072 · Decided May 4, 2022 · 530 days after receipt
Device type: AlzheimerS Disease Pathology Assessment Test (QSE) · Laboratory Medicine & Pathology
- Lumipulse G CA15-3510(k)
K192524 · Decided Sep 4, 2020 · 357 days after receipt
Device type: System, Test, Immunological, Antigen, Tumor (MOI) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.